Printer Friendly

Innovus Pharma Receives CPNP Notification to Commercialize Sensum+ in the European Union.

M2 PHARMA-March 9, 2017-Innovus Pharma Receives CPNP Notification to Commercialize Sensum+ in the European Union

(C)2017 M2 COMMUNICATIONS

- US-based specialty pharmaceutical company Innovus Pharmaceuticals, Inc. (OTCQB Venture Market: INNV) has eceived the CPNP notification number required to commercialise Sensum+ in all 28 member countries of the European Union, the company said.

Innovus Pharma currently partners Sensum+ internationally with Orimed in Canada, Tramorgen Ltd. in the United Kingdom, Elis Pharma in Turkey and certain select markets, BroadMed SAL for Lebanon, Ovation for Morocco, Khandelwal Laboratories, PVT, Inc. for India, Nepal, Bhutan, Sri Lanka and Bangladesh, Tabuk Pharma for select Middle Eastern countries, and Oz Biogenics for Myanmar and Vietnam.

Sensum+ is currently approved to be marketed and sold in 31 countries worldwide including the United States, Europe, India and Morocco.

In addition to the United States, the largest market for Sensum+, Innovus Pharma currently generates Sensum+ revenues from the following markets: the United Kingdom and Morocco.

Sensum+ is a non-medicated cream which moisturises the head and shaft of the penis for enhanced feelings of sensation and greater sexual satisfaction.

Reduced Penile Sensitivity results form a gradual loss of penile sensitivity over time. RPS is observed in diabetic patients, patients suffering from multiple sclerosis, 20% of patients undergoing hernia surgery and circumcised men.

Headquartered in San Diego, Innovus Pharma is an over-the-counter consumer goods and specialty pharmaceutical company engaged in the commercialisation, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:6MORO
Date:Mar 9, 2017
Words:266
Previous Article:US FDA Accepts Alexion's sBLA Filing of Soliris as for Refractory Generalised Myasthenia Gravis.
Next Article:CooperGenomics Receives ISO 15189 Accreditation in United Kingdom Laboratories for Noninvasive Prenatal Testing.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters